Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 2	2026-05-12		NCT01703949

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
University of Washington	397

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fred Hutch/University of Washington Cancer Consortium	Seattle	United States	140

Clinical trials